Eli Lilly (NYSE: LLY) led the way in pharma M&A during June. The US pharma major announced two major deals in the month, both ...

The GPRC5D-directed therapies market is witnessing robust growth, driven by high unmet need in relapsed/refractory multiple ...

The pulmonary arterial hypertension (PAH) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, UK ...

Actinogen Medical (ASX: ACW), an Australian biotech, announced that the 100th participant in its pivotal XanaMIA Phase ...

Austria’s HeartBeat.bio and biotx.ai have announced a strategic partnership to identify and validate novel therapeutic ...

Swissmedic has introduced a fast-track review process for clinical trial applications, aiming to speed up access to ...

Last week’s announcement of a Life Science Strategy from the European Commission, includes action to address long-standing ...

A Dutch appeals court has ruled that health insurers acted unlawfully in their group tender for three CDK 4/6 inhibitors, ...

Since July 2016, and in line with the Irish Pharmaceutical Healthcare Association (IPHA) Code of Practice for the ...

A privately held U.S.-based contract manufacturer, packager, and distributor specializing in pharmaceutical and nutraceutical ...

Japanese drugmaker Chugai Pharmaceutical has entered into a joint research and license agreement to develop novel therapies for age-related diseases with Singapore-based biotech Gero.

A nasal COVID-19 vaccine developed by US biotech CyanVac has produced encouraging results in an early trial, showing potential to offer broader immunity and easier delivery than current injections.